Titan Pharmaceuticals, Inc. (OTCBB:TTNP) Fills Gap Even Faster

Titan Pharmaceuticals, Inc. (OTCBB:TTNP) really took off on Monday, vaulting over the $1 levels to reach $1.16 on the day, on buying volumes of $3.6 million. The ticker added nearly 24% on the day, which was reserved for the beginning of a new review procedure from the FDA. The result of the procedure is unknown, but TTNP seems equipped with optimism, at least until the meetings happen in November, and maybe even after that, in case of a positive outcome.

While TTNP is not seeing another promotion like the one that boosted it in May, the ticker is becoming active after a summer in the doldrums, awaiting the development with the Probruphine anti-opioid treatment.

Message boards are wildly optimistic about this ticker, just as a few days ago there were warnings of a quick reversal. Spikes in pharmaceutical stocks are often a matter of hype and loyalty, and TTNP has a good past record, both in terms of real pharmaceutical business and in a responsive, actively traded stock.

The solid process of a new drug is a great booster for a pharmaceutical company. The rise in TTNP in a way resembles that of NanoViricides, Inc. (AMEX:NNVC), which fulfilled its promise to list to a higher tier, while continuing its drive to bring its dengue fever treatment to market. The larger exposure was certainly a factor, and NNVC doubled in price in three months, keeping above $5.20, and even touching $7 for a short period.

Another ticker that received excellent news, a large R&D grant, managed to double in price, from $1 to $2: Soligenix, Inc. (OTCBB:SNGX), though in the last few days it retreated from a peak around $2.40 and toward $2.

TTNP has the potential to attract longer-term investors, even beyond the November events. The eventual marketing of the anti-addiction treatment could offer support to the shares in the longer term. But between those events, the company may very well suffer a setback deep enough to wipe out a large part of investments.

The next few weeks will probably be promising buying time for TTNP, but do your own research of the company’s potential before you take up positions, and do not invest sums that you could not afford to lose.